Quark Pharma Completes Series A Funding Round to Expand Multi-Therapeutic Clinical Research Services

Recently, Quark Pharma successfully completed its Series A financing round, securing tens of millions of RMB in funding led by Taikun Fund, with participation from Peppermint Angel Fund and Guoshen Jianheng Fund. Against the backdrop of a global economic downturn and slowed pharmaceutical investment, Quark Pharma has bucked the trend, further demonstrating its comprehensive strength in clinical research services.

Radiopharmaceuticals are spearheading a revolution in the medical field, enabling true precision medicine. By 2030, the global radiopharmaceutical market is projected to surpass $20 billion, while the Chinese market is expected to achieve tenfold growth over the next decade. Since establishing radiopharmaceutical R&D services as its strategic direction in 2018, Quark Medicine has rapidly achieved a series of milestone accomplishments in the field of radiopharmaceuticals, includingAs a CRO, led the Phase III clinical trial for China’s first new product for detecting cancer bone metastasis, which successfully obtained marketing approval.. Through the accumulation of professional capabilities,Quark Pharma has established a comprehensive and efficient service system for the clinical research of radiopharmaceuticals.。

Quark Pharma not only holds a leading position in the field of radiopharmaceuticals but has also extended its deeply cultivated service philosophy to other key areas, including Central Nervous System (CNS) disorders and Gene and Cell Therapy (CGT), by leveraging the technology and experience accumulated in this sector. The high-barrier technologies, clinical execution capabilities, and study design expertise from the radiopharmaceutical field are equally prominent in these emerging sectors, creating a synergistic effect where “1+1>2.”

Mr. Yuan Dawei, CEO of Quark MedicineHe stated, “This round of financing will not only drive Quark Medicine’s further in-depth development in the field of radiopharmaceuticals, but also empower the company to comprehensively enhance its multi-center clinical service capabilities. Building on our existing efficient team and well-established service chain, we will deliver more precise and professional clinical solutions. Quark Medicine’s vision is to provide high-quality professional services by deeply cultivating and focusing on niche sectors, thereby helping clients achieve outstanding research outcomes and promoting the development of the entire industry.”

Leveraging its core competencies accumulated in focused areas, Quark Medicine has comprehensively enhanced the maturity and professionalism of its services. The company’s established high-efficiency service system for the entire clinical research process has not only improved the efficiency and quality of clinical trials but also saved clients significant time and resources. Looking ahead, Quark Medicine will continue to refine its radiopharmaceutical service chain and comprehensive clinical research capabilities, aiming to provide clients with more comprehensive, higher-quality services and become a CRO partner with an outstanding reputation.

Quark Pharma, founded in 2011, is a professional clinical CRO specializing in nuclear medicine. Headquartered in Beijing, the company maintains branches and offices in Shanghai, Guangzhou, Hangzhou, Chengdu, Wuhan, Zhengzhou, Shenyang, and other regions. Its comprehensive suite of clinical research services encompasses bioanalysis, clinical studies for innovative drugs, clinical studies for generic drugs, biostatistics, and Independent Review Committee (IRC) services. Additionally, Quark Pharma provides international regulatory registration services covering Europe, Australia, North America, and other regions. The company is continuously exploring the integration of artificial intelligence with clinical research and deepening the digital transformation of clinical management.

Upholding the service philosophy of “Accompanying Growth, Empowering Client Success,” Quark Pharma always places client value first. With 13 years of development, the company has accumulated extensive experience in nuclear medicine, neuropsychiatry, cell and gene therapy, oncology, cardiovascular and cerebrovascular diseases, and respiratory disorders. In the pharmaceutical industry, we are undeterred by the passage of time; we firmly believe in long-termism, accompanying growth with sincerity and facilitating success with professionalism.